Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten

Whitefort Urges Arbutus Biopharma To Strike Deals, Not Dilute Shares - Finimize

Finimize

Whitefort Urges Arbutus Biopharma To Strike Deals, Not Dilute Shares - Finimize

Finimize

Whitefort Urges Arbutus Biopharma To Strike Deals, Not Dilute Shares - Finimize

Finimize

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value - Chronicle-Tribune

Chronicle-Tribune

Short Interest in Arbutus Biopharma Co. (NASDAQ:ABUS) Grows By 12.4% - MarketBeat

MarketBeat

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 12.4% in April - Defense World

Defense World

Nothing is Better Than Arbutus Biopharma Corp (ABUS) stock at the moment – Sete News - SETE News

SETE News

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average of $2.44 - MarketBeat

MarketBeat

Arbutus Biopharma (NASDAQ:ABUS) Stock Crosses Above 200-Day Moving Average of $2.44 - Defense World

Defense World

What technical indicators reveal about ABUS stock – US Post News - US Post News

US Post News

Arbutus to Participate in Two Upcoming Investor Conferences - Yahoo Finance

Yahoo Finance

Arbutus to Participate in Two Upcoming Investor Conferences - Yahoo Finance

Yahoo Finance

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average of $2.39 - MarketBeat

MarketBeat

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Passes Above Two Hundred Day Moving Average of $2.39 - Defense World

Defense World

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

GlobeNewswire Inc.

Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 ... - MyChesCo

MyChesCo

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Zacks Investment Research

Arbutus Biopharma Corp (ABUS) presents a great opportunity, but the stock is slightly overvalued – US Post News - US Post News

US Post News

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? - Yahoo Finance Australia

Yahoo Finance Australia

Arbutus Biopharma presents new PD-1/PD-L1 interaction inhibitors - BioWorld Online

BioWorld Online

Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? – US Post News - US Post News

US Post News

Moderna Investors Should Beware Patent-Dispute Fallout (NASDAQ:ABUS) - Seeking Alpha

Seeking Alpha

SG Americas Securities LLC Increases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Defense World

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire Inc.

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance

Yahoo Finance

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

GlobeNewswire Inc.

Investors in Arbutus Biopharma (NASDAQ:ABUS) from five years ago are still down 25%, even after 12% gain this past week - Simply Wall St

Simply Wall St

Arbutus Biopharma stock jumps amid claim construction order in patent fight with Moderna - Seeking Alpha

Seeking Alpha

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? - Yahoo Canada Finance

Yahoo Canada Finance

ABUS Stock Quote Price and Forecast - CNN

CNN

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire Inc.

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials - Yahoo Finance

Yahoo Finance

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

GlobeNewswire Inc.

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

GlobeNewswire Inc.

Arbutus Biopharma CEO to retire as company cuts workforce by 24% - The Business Journals

The Business Journals

Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results - Yahoo Finance

Yahoo Finance

Arbutus, Genevant Mustn't Dodge Vaccine Tech Suit, Acuitas Urges - Bloomberg Law

Bloomberg Law

Arbutus BioPharma narrows research focus to extend cash runway - The Business Journals

The Business Journals

Arbutus Sued in New Venue on Pfizer Covid Vaccine Delivery Tech - Bloomberg Law

Bloomberg Law

EdgarFiling - SEC.gov

SEC.gov

Arbutus touts the Phase II success of its RNAi treatment for Hepatitis B - Clinical Trials Arena

Clinical Trials Arena

Arbutus: Hunting a Functional Cure for Chronic Hepatitis B Infection - BioBuzz

BioBuzz

Incorporated References Can Be Used in an Anticipation Rejection - JD Supra

JD Supra

US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma - Yahoo Finance

Yahoo Finance

Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight - Yahoo News UK

Yahoo News UK

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots - Yahoo Finance

Yahoo Finance